Those patients with tumours showing high KANK1 protein expression had significantly better 10 years BCSS (p = 0.024; Fig. 2b) and longer TTDM (p = 0.048; Fig. 2c) compared with those patients showing low/reduced KANK1 expression. This evidence concerns the gene KANK1 and neoplasm.